Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive

 
• By Brenda Sandburg
  
osteoarthritis
There are many obstacles to developing disease-modifying osteoarthritis drugs. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D